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A Review of the Models of Schizophrenia: And a putative novel, more unified 
model 
Michael Vogel Bronstein 
Washington and Lee University 
Abstract 
Schizophrenia is a debilitating disease state which causes immense pain to sufferers and to their families. Although 
some proximate causes of symptoms of the disease have been identified, no ultimate cause has been uncovered 
which can explain all of the symptoms. This paper presents a novel theory of the ultimate cause of some forms of 
chronic schizophrenia with the potential to explain many (if not all) symptomologies associated with the disease. In 
addition to its explanatory power, this putative model may also give rise to new early diagnostic tools and 
treatments for schizophrenia. After the model is fully explained, suggestions for further research to confirm this 
model's validity are put forth. 
Introduction 
Schizophrenia is a disease which is part 
of the set of human psychotic disorders and 
which effects about 1% of the population 
worldwide. This disease has been shown to 
have a strong genetic component, with a 
heritability of around 80% (Rapoport et. al., 
2005). Although the genetic basis of 
schizophrenia is well established, the details 
surrounding the specific loci of inheritance 
are sparse save that there are likely to be 
multiple loci involved instead of just a 
single gene (Kopala et. al., 2001). Likewise, 
the physiological basis of the onset of 
psychosis is unknown (Duncan et. al., 1999). 
Despite the lack of ultimate certainty in the 
underlying causes of this disease, several 
models have been proposed in the literature 
thus far. 
One such model is the N-Methyl-D-
Aspartate (NMDA) hypothesis of 
schizophrenia. NMDA is a specific agonist 
for a subset of glutamate receptors called 
NMDA receptors, which help to regulate the 
membrane potential of the cell (Haack et. 
al., 1990). The NMDA model hypothesizes 
that the hypofunction of NMDA receptors is 
the underlying cause of schizophrenia. This 
model was proposed because the actions of 
ketamine and phencyclidine (PCP) can both 
cause and exacerbate psychotic symptoms  
similar to schizophrenia, and both block 
NMDA receptor activity. The hypofunction 
of NMDA receptors could in theory generate 
a pattern of dopaminergic dysregulation 
which could in turn further negatively 
impact NMDA systems (Laruelle et. al., 
2003). These irregularities in the dopamine 
system, which are accounted for in the 
proposed theory below, could lead to 
decreases in nitric oxide levels because 
NMDA receptor stimulation results in 
calmodulin mediated increases in nitric 
oxide synthase [and in turn nitric oxide] 
(Coyle, 2013). Since nitric oxide mediated 
vasodilation is central to the theory proposed 
in this paper, the above points render the 
NMDA hypothesis largely subsumed by the 
proposed model. Although the NMDA 
hypothesis accounts for several facets of the 
schizophrenic disease state, it is inadequate 
as it has several shortcomings. For example, 
one important shortcoming of the NMDA 
model is that it fails to explain the lack of 
power of agents that reduce the toxicity of 
NMDA antagonists in the treatment of 
schizophrenia when used alone (Olney et. 
al., 1999). These shortcomings necessitate 
the exploration of a second model. 
A second model of schizophrenia is the 
dopamine hypothesis. This model 
hypothesizes that the onset of the disease is 
characterized by abnormal dopamine 
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processes. In its current form, a 
hypodopaminergic state occurs in the frontal 
regions, causing negative symptoms, while a 
hyperdopaminergic state in the ventral 
tegmental area results in psychosis (i.e., 
positive symptoms). There are numerous 
shortcomings of the dopamine hypothesis, 
including a lack of evidence of abnormally 
high dopamine levels, along with the low 
affinity for dopamine receptor subclasses of 
certain anti-psychotics (Duncan et. al., 
1999). Additional shortcomings include the 
fact that some anti-psychotics, such as 
Haloperidol, actually significantly increase 
dopamine receptor binding potential when 
used long term (Silvestri et. al., 2000). 
Despite these failures, the dopamine theory 
is currently still a predominant theory, and is 
subsumed by the model proposed in this 
paper with modifications which make up for 
many of its shortcomings. For example, the 
model proposed in this paper includes an 
alteration in the ratio of D 1/D2 receptor 
activity. This does not necessitate an overall 
increase in either dopamine receptors, 
metabolites, or dopamine itself. Again, the 
shortcomings of the dopamine hypothesis 
necessitate the exploration of a third model 
of schizophrenia. 
A third model of schizophrenia is the 
attentional or information processing model 
of schizophrenia. This model draws from the 
above neurotransmitter models with a focus 
on the attentional component of the disease. 
Evidence for this model comes from several 
sources, including work by Takahashi et. al. 
(2010) which states that schizophrenics 
cannot 	 effectively 
	 gate 	 irrelevant 
sensorimotor and cognitive information, and 
which shows neural substrates for 
accompanying (and perhaps proximately 
causal) deficits in mismatch negativity 
(MMN) and P3a in schizophrenics. These 
neural substrates implicate widespread 
attentional network abnormalities in the  
brains of schizophrenics. Further evidence 
comes from work by Swerdlow et. al. (2008) 
which suggests that, in humans and in mice, 
NMDA antagonists can disrupt pre-pulse 
inhibition (PPI). Incidentally, PPI is also 
reduced following the administration of 
phencyclidine (PCP), which is used to create 
a model of schizophrenia commonly used in 
experimental animals. The information 
processing deficits seen in this model can be 
accounted for by an alteration in the D 1/D2 
receptor activity ratio. Because such an 
alteration is incorporated into the proposed 
model in this paper, the information 
processing model of schizophrenia is 
subsumed by the model proposed in this 
paper. 
A final model of schizophrenia, the PCP 
model, is also subsumed by the model 
proposed in this paper. The PCP model of 
schizophrenia is based on the fact that the 
induction of psychosis can be achieved by 
administering PCP. This induction of 
psychosis may be in part mediated by 
cardiovascular system effects of the drug. 
This is supported by the fact that rats given 
PCP 	 have 	 changes 	 to 	 their 
electrocardiogram completely blocked by 
either Haloperidol (an anti-psychotic 
effective in treating schizophrenia) or the 
vasodilator agent nitroglycerine (Shi & Xu, 
1994). This suggests that the efficacy of 
Haloperidol in treating schizophrenia is 
partially mediated by the ultimate effects of 
its administration on the cardiovascular 
system (see later explanation of these effects 
and the drug's efficacy). This also suggests 
that the effects of PCP are in part mediated 
by cardiovascular effects. Additional 
support for this concept comes from the fact 
that in rats nitric oxide (NO) mediates 
vasodilation, which is effected by oestrogen 
and also is shown to increase after PCP 
administration (Palsson et. al., 2010). This 
response appears to be compensatory, as it is 
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temporally shifted with respect to the 
maximum behavioral effects of the drug. 
Interestingly, this effect occurs most in the 
prefrontal cortex and ventral hippocampus, 
two areas implicated in schizophrenia. The 
combination of all of the above information 
provides further support for the putative 
model put forth in this paper by suggesting 
the role of cardiovascular deficits having a 
role in the ability of PCP to create a model 
of schizophrenia in individuals to whom it is 
administered. Thus, there is the possibility 
that the model which will be proposed in the 
subsequent section subsumes the PCP model 
of the disease. This potential is supported by 
the work of Palsson et. al. (2010), which 
states that there is support in their data for 
"an interaction between PCP and a stress 
response converging on the NO signaling 
pathway." 
Unfortunately, 	 none 	 of 	 the 
neurotransmitter models currently proposed 
adequately account for the symptomology, 
progression, and treatment of chronic 
schizophrenia. Thus it is necessary to 
propose a new model which has an 
underlying cause not based in 
neurotransmission itself and which 
integrates the strengths of current 
hypotheses while accounting for their 
shortcomings. The model proposed in this 
paper fulfills this role for chronic forms of 
schizophrenia (it does not attempt to account 
for more acute forms of the disease). An 
outline of the proposed model, as well as 
supporting evidence, will be explored in the 
next section. 
Proposed Model 
Several observations in schizophrenics 
prompted the model of schizophrenia 
proposed here. First of all, although micro-
level events occurring in the brains of 
schizophrenics would not be detectable with  
the spacial resolution of imaging techniques 
such as magnetic resonance imaging (MRI), 
they may manifest on a macro level as gross 
structural abnormalities. Such macro level 
abnormalities are apparent in many MRI 
studies, including Rupp et. al. (2005). 
Secondly, impairments in vasodilation in 
schizophrenics have been found in several 
studies, including Turenne et. al. (2001) and 
Hudson et. al. (1997). Third, schizophrenics 
have increased levels of nitric oxide 
synthase (NOS, the enzyme which 
catabolizes nitric oxide) in the cortex 
(Karson et. al., 1995), which may be an 
attempt to compensate for impaired 
vasodilatory response to nitric oxide (like 
that seen in those with oestrogen resistance). 
Fourth, schizophrenics respond positively to 
treatment with oestrogen (Hafner, 2003), 
and tend to have low blood oestrogen levels 
(Rossler & Hafner, 1993). Fifth, women 
tend to develop symptoms of schizophrenia 
during points in the menstrual cycle with 
lower oestrogen levels. This effect was so 
marked that "menstrual psychosis" was 
listed as a separate diagnostic category in 
the early 1900s. This effect is mirrored 
across the female life cycle, as late onset 
schizophrenia (after age 40-45) is much 
more prevalent in females than males and is 
associated with a loss of ovarian functioning 
starting at about the same age (Rossler & 
Hafner, 1993). Finally, individuals 
(including 	 non-schizophrenics) 	 with 
oestrogen resistance tend to exhibit deficits 
in nitric oxide mediated vasodilatation, 
especially in response to ischemic events 
(Faustini-Fustini et. al., 2009). 	 These 
observations, 	 when 	 considered 
simultaneously, suggest a oestrogen 
mediated deficiency in vasodilatory 
response to ischemic stimuli in 
schizophrenics. This deficiency may result 
in micro-ischemic events, micro-infarct, and 
general functional instability at a micro 
circuit level. This may be further 
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exacerbated by the impaired glucose 
tolerance (IGT) of medication naive first 
episode schizophrenics reported by Collins 
et. al. (2003) as IGT has been associated 
with increased risk of ischemic stroke (e.g., 
in diabetes). This suggestion of micro-
ischemic events and micro-infarcts in 
schizophrenics, mediated by an oestrogen 
influenced deficiency in nitric oxide 
mediated vasodilatory response to ischemic 
events, forms the core of the novel putative 
model proposed here to account for the 
deficits and abnormalities seen in chronic 
schizophrenia. 
This model has surprisingly great 
explanatory value as a putative ultimate 
cause of some forms of chronic 
schizophrenia. For example, the observed 
levels of higher neural noise in 
schizophrenics can be explained with this 
model if there are differential effects of 
unstable oxygen supply on D1 vs. D2 
receptor systems, as the D 1/D2 activation 
ratio is crucial for maintaining stability of 
the representations of internal and external 
stimuli in local circuits and for optimizing 
noise levels in these circuits (Winterer et. 
al., 2004). Such differential effects on D1 
and D2 receptor activity after ischemia is 
seen in Mongolian gerbils, and consists of a 
decrease in the number of D2 binding sites 
in the striatum along with an accompanying 
decrease in D1 receptor affinity which is 
more widespread (Chang et. al., 1993). If 
these changes generalize to humans, they 
provide a putative mechanism for the 
alteration in D 1/D2 receptor activity ratio. 
Further, since D2 agonists exert 
neuroprotective effects in rats by decreasing 
neuronal activity levels (O'Neil et. al. 1998), 
this change in the number of D2 receptor 
binding sites (if it generalizes to humans) 
may provide a positive feedback mechanism 
for increasing the likelihood of future 
ischemic events as decreasing the number of  
D2 binding sites would be the functional 
equivalent of a D2 receptor antagonist. 
Indeed, such a relationship between 
disturbed dopamine production and an 
increase in the risk of ischemic stroke is 
strongly suggested by the observed increase 
in ischemic stroke in Parkinson's disease 
patients (Chang et. al., 1993). If this holds in 
schizophrenics, it would create a positive 
feedback mechanism such that each 
ischemic stroke increases the likelihood of 
another, thereby ensuring chronically high 
neural noise levels in this population. 
The increase in neural noise levels 
generated in this manner may help to 
explain 	 the 	 decoupling 	 between 
physiological markers and behavioral 
outcomes observed in schizophrenia. One 
example of this decoupling is the finding 
that larger left temporal lobe volumes were 
associated with better odor identification in 
controls but not in schizophrenics (Moberg 
et. al., 2006). A second example of this 
decoupling is the finding by Kayser et. al. 
(2010) that olfactory event-related potentials 
(ERPs) were substantially less related to 
odor intensity and subsequent identification 
in schizophrenics (vs. controls). A third 
example of this decoupling is the possible 
disassociation reported by Manor et. al. 
(1999) between attentional allocation 
(visual) and eye fixation location in 
schizophrenics. A final example of this 
decoupling is the fact that the correlation 
between olfactory bulb volume and 
olfactory abilities in healthy subjects 
(independent of age), reported by 
Buschhuter et. al. (2008), is not present in 
schizophrenics (c.f., Turetsky et. al., 2003). 
The wide range of domains in which this 
decoupling is found suggests a global level 
parameter is disrupted in schizophrenia. 
Alterations in levels of neural noise certainly 
conform to this suggestion. 
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The increase in neural noise levels 
generated by the alteration of D 1/D2 
receptor activity may also help to explain 
the deficits in olfaction present in 
schizophrenics, because according to signal 
detection theory this should decrease 
sensitivity and increase rates of false alarms 
of odor presence (i.e., hallucinations). This 
increase is consistent with the olfactory 
hallucinations experienced by some fourteen 
percent of patients (Stevenson, 2013). These 
deleterious effects of neural noise on 
olfaction should be amplified by causal 
fluctuations in blood oxygen level putatively 
experienced by schizophrenics, as these may 
reduce the reliability of neural responses 
further by limiting the resources available to 
make the optimal response. 
In addition to this explanation of 
olfactory deficits, the model put forth in this 
paper also explains a second abnormality 
which could contribute to the olfactory 
deficits in schizophrenia. This abnormality, 
identified by Turetsky et. al. (2003), is that 
schizophrenics exhibit increased protein 
expression of Growth Associated Protein 43 
(GAP-43). This suggests that schizophrenic 
patients have difficulty establishing or 
maintaining synaptic connections between 
the olfactory bulb and epithelium. The 
unstable oxygen supply assured by the 
proposed model would certainly increase the 
difficulty in maintaining viable connections 
between these two locations, and could thus 
help to explain the results found. Since the 
olfactory system depends on memory to 
compare odors, the high vulnerability of the 
hippocampus to ischemic damage would 
further mediate deficits in olfaction under 
this model. Such damage would also explain 
the verbal memory deficit present in 
schizophrenia. 
The model proposed in this paper would 
also account for the attentional deficits that  
have been recently more prominently 
associated with schizophrenia (e.g. 
Swerdlow et. al., 2008; Takahashi et. al., 
2010). Thus, the attentional model of 
schizophrenia is subsumed by the proposed 
model. This attentional phenotype could be 
explained by the fact that attentional 
maintenance requires energy, for which a 
consistent supply of glucose and oxygen 
(both delivered via the blood) are required. 
Further, the delusional thinking present in 
schizophrenia could be explained by the 
putatively increased neural noise levels 
combined with a lack of mode two 
processing (inducing both erroneous results 
and the lack of the depth of reason necessary 
to debunk them) in schizophrenics. This 
possibility is supported by a study by 
Masicampo et. al. (2008), which found that 
blood glucose levels manipulated with 
lemonade alone could induce processing 
level differences (compared to a control 
group). It stands to reason that this would 
also apply to inconsistent oxygen supply (as 
would occur with improper ischemic 
vasodilation) in schizophrenics as oxygen is 
required for the cellular respiration 
necessary to utilize the glucose obtained 
from the blood. 
In addition to explaining these more 
internal deficits, interactions with the larger 
environment can be explained using the 
proposed model as well. One example of 
such an interaction is that between 
schizophrenics and nicotine. Many studies 
have found that schizophrenics smoke 
significantly more packs per day than 
controls (e.g. Rupp et. al., 2005). This can 
be explained by the putative model plus two 
additional factors. The first of these factors 
is that schizophrenics tend to have impaired 
vasodilation response to nicotinic acid 
(formed in the blood after smoking tobacco). 
The second factor is that metabolites of 
nicotine, such as cotinine, cause vasodilation 
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to occur. These factors taken together 
suggest that schizophrenics, on average, 
would have to smoke more cigarettes to 
achieve the vasodilatory results of cigarette 
smoking. The proposed model provides the 
impetus to smoke in the first place: to 
achieve short term alleviation of the 
reduction in vasodilation in response to 
ischemic stimuli. Unfortunately, it is likely 
that long-term, this is maladaptive because 
the build-up of carbon monoxide and 
dioxide in the blood will create the very 
conditions that the patient attempted to 
alleviate in the first place (micro-ischemic 
events) by lowering the amount of oxygen in 
the blood. This effect should become more 
pronounced with higher pack-per-day loads. 
The above points make it apparent that there 
would be a positive feedback loop between 
smoking behavior and symptomology in 
schizophrenics. This possibility places even 
greater importance on controlling for the 
effects of smoking when studying 
schizophrenia. 
In addition to both internal and 
behavioral traits of the disease, the proposed 
model can help account for the efficacy of 
several treatments for schizophrenia. One 
such treatment is Haloperidol, an 
antipsychotic medication for which there 
exists a wide variation in the time it takes to 
achieve clinical response (as defined by a 
20% reduction in symptomology). Within 
this variation, it takes 8 weeks for 90% of 
patients to achieve clinical response. This 
suggests that long term compensatory 
changes mediate the efficacy of this drug 
(see below for details on this mechanism). 
Despite the large time delay in achieving 
efficacy, response to treatment within a 
single week is highly predictive of clinical 
response at 8 weeks. In fact, only 40% of 
those who had not responded after 1 week of 
treatment achieved clinical response after 
four weeks (Emsley et. al., 2006). This  
suggests the contribution of more short term 
mechanisms to the efficacy of Haloperidol 
as well. 
The short term actions of Haloperidol 
are consistent with the proposed model as 
Haloperidol is a D2 receptor antagonist 
(likewise, many antipsychotics are 
dopamine receptor antagonists). In the short 
term, Haloperidol would therefore have the 
effect of increasing the amount of synaptic 
dopamine by blocking the binding of 
dopamine to available receptors. Dopamine 
has been found to be able to induce 
microvascular vasodilation in the brain in an 
effect at least partially mediated by D 1/D5 
receptors. This is especially so in the 
striatum (Choi et. al., 2006). Thus, a 
dopamine receptor antagonist (like 
Haloperidol) 	 should 	 increase 	 the 
vasodilatory effects of dopamine, which 
should prove to be neuroprotective. In 
schizophrenic males, this effect should be 
compounded by the fact that in one third of 
the male schizophrenic cohort Haloperidol 
causes an increase in oestrogen levels 
(Rossler & Hafner, 1993), thus helping to 
counteract the problem of a oestrogen 
mediated issue in nitric oxide induced 
vasodilation. This neuroprotection should 
occur by augmenting schizophrenics' poorly 
functioning nitric oxide mediated 
vasodilatory pathway, and thus increasing 
oxygen availability during potential 
ischemic events (i.e., helping to prevent 
ischemia from occurring). 
The long term effects of Haloperidol are 
also consistent with the proposed model 
because Haloperidol has been shown to 
engender an average increase, compared to 
the age-corrected baseline values derived 
from the eight antipsychotic-naive control 
subjects, of 34% in the D2 binding potential 
(a combined measure of affinity for a 
receptor and receptor density) in a group 
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consisting of both novel and traditional 
antipsychotic patients (Silvestri et. al., 
2000). This long term D2 receptor activity 
up-regulation may well provide the 
additional efficacy which causes many 
patients to achieve clinical response after 
several weeks of treatment. This is 
consistent with findings by O'Neil et. al. 
(1998) which suggest that increasing D2 
activity is neuroprotective in rats (this is 
more fully discussed above). This 
neuroprotective effect should be further 
augmented since sensitivity of D2 receptors 
is negatively correlated with amount of 
oestrogen present (Hafner et. al., 1991). 
Because of this and the fact that 
schizophrenics tend to have reduced serum 
oestrogen (Rossler et. al. 1993), they should 
also exhibit increased dopamine receptor D2 
sensitivity. The combination of this 
increased sensitivity to D2 activity and its 
up-regulation 	 should 	 be 	 highly 
neuroprotective. This notion, in confluence 
with that in the preceding paragraph, 
demonstrate that the proposed model 
accounts for both the long term and short 
term efficacy of antipsychotics in providing 
protection against (short term) and 
mitigating the results of (long-term) 
oestrogen mediated micro-ischemic events 
in schizophrenics. 
Haloperidol and other medications used 
to treat schizophrenics are also consistent 
with the model proposed in this paper 
because schizophrenics who are medicated 
display a drop in the amount of entropy in 
their resting electroencephalogram (EEG) 
compared to their pre-medication levels 
(Fernandez et. al., 2013). Entropy (when 
applied to EEG) measures the predictability 
of future EEG activity from previous 
activity, with increased entropy indicating a 
decrease in the predictive value of this 
previous activity. The predictive value of 
previous activity should, by definition, be  
decreased by increases in the level of neural 
noise in the brain of the individual whose 
EEG is being recorded (thus increasing 
entropy levels). Because of this, entropy is 
an indirect measure of the levels of neural 
noise in the brain. Therefore, the decrease in 
entropy levels in medicated schizophrenics 
is consistent with the idea that mechanisms 
that induce neural noise increases in the 
brains of schizophrenics are causal in 
producing the disease's symptomology 
because medication decreases both neural 
noise levels and symptomology in 
schizophrenics. 
The model proposed in this paper is also 
consistent with the treatment value of a 
more recent medication used in the 
treatment of schizophrenia, namely 
recombinant human Erythropoietin (EPO). 
EPO has been shown to improve cognitive 
symptoms of schizophrenia and attenuate 
progressive gray matter loss in 
schizophrenic men when a high dose was 
administered weekly (Ehrenreich et. al., 
2010). This is consistent with the model 
proposed in this paper because EPO is 
widely used as a neuroprotective agent. 
Notably for the purposes of this paper, EPO 
was successfully used (by the same 
researchers) in the prevention of damage 
from ischemic stroke for several years 
before it was successfully tried as an adjunct 
treatment for schizophrenia. The treatment 
value of EPO in reducing ischemic stroke 
damage, loss of tissue (which could 
conceivably result from such damage) in 
schizophrenics, and the cognitive symptoms 
of schizophrenia establishes a further 
correlation between these reduced factors, 
which supports the proposed model's 
intertwining of them. 
A final feature of schizophrenia that can 
be explained by this model is the course of 
the disease itself. One debate in the literature 
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has been whether schizophrenia is simply a 
neurodevelopmental disease or is a 
neurodegenerative one as well (Duncan et. 
al., 1999). The model proposed here 
reconciles many of the features of this 
debate in the following manner: in this 
model, during the initial prodromal period, 
symptoms are caused by the instability of 
blood oxygen flow to brain areas. This 
prodromal period is usually delayed in onset 
until adolescence for several reasons. The 
first of these is cerebral oxygen demand 
(CMRO2) increases with age, peaking at 21-
30 (Hafkenschiel et. al., 1953). This, 
incidentally, includes the range of age of 
onset most common for schizophrenia. 
Although this study was conducted in 
hypertensive patients, they provide 
extensive evidence showing that this group 
does not differ from normal in CMR02. 
levels (and additionally, as will be discussed 
later, hypertension occurs often in 
schizophrenia). The trend found in this study 
suggests that the putative deficits of oxygen 
supply to the brain present in schizophrenics 
are not severe enough to manifest until 
blood oxygen demand (and thus, to a certain 
degree, vulnerability to ischemia) increases. 
The late age of onset of the disease can also 
be explained with evidence from a mouse 
model suggesting a higher vulnerability of 
white matter to ischemic damage with 
increasing age (Baltan et. al., 2008). If this 
generalizes to humans, then this would also 
help to explain the later onset of the disease 
(because ischemia will be less detrimental 
earlier in life). 
When the prodromal period does begin, 
little micro-infarct occurs as a result of the 
deficiencies present in schizophrenics 
because of the protective effects of brain-
derived neurotrophic factor (BDNF). This 
allows for some progression of the disorder, 
but minimal overall effect compared to what 
is to come. At this point of dynamic  
equilibrium, gross structural abnormalities 
are progressively accrued, increasing the 
patients' vulnerability to a causal stressor 
over time (hence the high age of formal 
onset of the disease). Such a stressor may 
upset this dynamic equilibrium as stress has 
been shown to decrease BDNF levels 
(Bremner, 1999). This effective reduction in 
the amount of BDNF protection afforded 
neurons would be compounded due to 
abnormalities in the expression of BDNF in 
schizophrenics reported by Asche et. al. 
(2001), such as reduced serum BDNF, 
reduced Messenger Ribonucleic Acid 
(mRNA) for BDNF, and an allele variant of 
BDNF in some patients. At this point, the 
formal onset of the disease may occur due to 
micro infarct (and increased effects of 
ischemia due to accrued structural 
abnormalities) in vulnerable areas. This 
relatively larger and more sudden 
accumulation of damage may account for 
the phenomenon of a "schizophrenic break" 
[to use a familiar analogy: this situation 
mirrors the action of neurons upon one 
another in engendering an action potential 
where structural changes accrue in the form 
of opening and closing ion channels, and 
eventually, given a 'causal' stressor, these 
changes will overcome the threshold for 
firing at the axon hillock, and an action 
potential will ensue]. The results of this 
break should vary according to the unique 
pattern of structural abnormalities accrued 
during the prodromal period and the 
resulting differing vulnerabilities to 
decreased reliability of blood oxygen in 
separate areas of the brain. These structural 
abnormalities, through their interaction with 
individual differences in both the stress of 
the disease itself (causing a further reduction 
in BDNF) and in the amount of BDNF 
suppression caused by this stress, should 
determine the chronic nature and the unique 
course of the disease in each individual. 
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After this schizophrenic break occurs, 
the degeneration generally peaks and 
symptoms begin to gradually lessen. The 
great capacity of humans to adapt to 
stressful situations can explain this 
phenomenon, as gradually the disease state 
becomes less stressful, and thus levels of 
BDNF may rebound. This process of 
symptom reduction may then be augmented 
by long term plasticity of the human brain, 
and by the fact that a relatively small 
number of new neurons are continuously 
generated in the adult brain (Johansson et. 
al., 1999). Both of these facts may lead to 
adaptations to the damage that has occurred, 
and thus a reduction in overall 
symptomology. The lack of progression of 
the disease after a certain point may also be 
attributed to the severity of the micro 
ischemia, which may not be severe enough 
to effect many areas of the brain. This would 
mean that after a period of degeneration, the 
disease would cease to progress as it would 
have effected all areas within this threshold. 
This model of the disease course is 
consistent with the findings of Asche et. al. 
(2001), which suggest that there is a role of 
BDNF in schizophrenia. Further, it is 
consistent with the well documented ability 
of stress to precipitate the onset of as well as 
relapses in schizophrenia. Finally, the micro 
ischemia model is also supported by 
findings that reduced chances of recovery 
occur, along with increased residual 
symptoms, after each relapse (Duncan et. al., 
1999), as each relapse signifies a period of 
more rapid accrual of damage. 
Now that the basic support for this 
model has been established, it is worth 
exploring several conclusions that follow 
from this model. One such logical sequel to 
the idea that the symptoms of schizophrenia 
are mediated by an oestrogen deficit 
resulting in vascular dysfunction is that the 
rates of coronary heart disease (CHD)  
should be increased in patients over 
controls. Indeed, this is the case: a study by 
Cohn et. al. (2004) found that the ten year 
risk of myocardial infarction is higher in 
patients (both male and female, although 
only significant for the men) than in a 
control population. This risk increase cannot 
be explained by the increase in smoking 
rates alone, nor can it be explained by 
increases in total cholesterol levels. This 
suggests that something must be 
physiologically abnormal in schizophrenics' 
vascular systems, just as the model put forth 
here postulates. This is supported further by 
findings in many studies that there are 
region-specific reductions in blood flow in 
the brains of schizophrenics, and that these 
correlate with negative symptoms (c.f., 
Coyle, 	 2013). 
	
Interestingly, 	 the 
schizophrenics studied by Cohn et. al. (all 
inpatients) had a two times higher risk for 
metabolic syndrome, which includes 
hypertension, compared to controls. The 
huge increase in the prevalence of this 
disorder in this population of people with 
the worst symptoms (those who are 
inpatients) 	 among 	 their 	 cohort 
(schizophrenics) suggests that high blood 
pressure makes the symptoms of 
schizophrenia worse. This is consistent with 
the model of ischemia mediating 
schizophrenic symptoms, as high blood 
pressure and metabolic syndrome would put 
additional strain on an already stressed 
cardiovascular system. 
Additional support for the idea that 
increases in blood pressure are detrimental 
to schizophrenics comes from the 
combination of the findings of two studies. 
The first finding is from a study by 
Robertson et. al. (1978), which showed that 
caffeine causes mean blood pressure to rise 
14/10 mm of mercury one hour after 
caffeine ingestion in healthy controls (in 
short, caffeine can cause acute blood 
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pressure increases). This finding is 
augmented by that of Lucas et. al. (1988) 
which showed that 10mg/kg of caffeine 
administered to schizophrenics worsens 
several measures of the presence of 
psychosis and increases diastolic blood 
pressure in schizophrenics. These two 
finding's confluence is consistent with the 
idea that increased blood pressure can 
worsen schizophrenia symptoms, and thus 
provides additional evidence for micro-
ischemic events as the proximate cause of 
schizophrenic symptoms. Further support 
for this (and thus the proposed model) 
comes from a recent study by Hallack et. al. 
(2013) which found that a single dose of 
nitroprusside caused a persistent (for 2 
weeks after treatment) and rapid reduction 
in symptoms in schizophrenics (Coyle, 
2013). Although these results are still being 
treated with caution due to the experimental 
design, this finding (if sound) is significant 
because nitroprusside is used clinically to 
reduce blood pressure in hypertensive 
individuals. In addition to its ability to cause 
a reduction in blood pressure, nitroprusside 
can cause vasodilation, thus increasing 
cerebral perfusion. This action of 
nitroprusside combined with its positive 
effect on schizophrenics is also consistent 
with the proposed model because it would 
allow for increased oxygen supply to the 
brain (and thus a reduction in ischemic 
events) while helping to ensure vasodilation 
when these events occur. 
It is important to note that although the 
above points offer seem to offer a simple 
avenue to treat schizophrenia (namely, 
increasing NO levels with treatments such as 
nitroprusside), this should be done with 
caution for several reasons. The first of these 
reasons is that nitric oxide may activate the 
Hypothalamic-Pituitary-Adrenal (HPA) axis 
(Palsson et. al., 2010). This suggests that the 
increases in nitric oxide levels (which may  
in the short term help to compensate for 
resistance to the chemical's vasodilatory 
effects) which occur in schizophrenics 
(Karson et. al., 1995) may actually be 
maladaptive long term because this increase 
may amplify stress responses. The second of 
these reasons is that nitric oxide is 
associated with the generation of neurotoxic 
reactive oxygen species. As mentioned 
above, these cautions may also apply to 
treatments targeting NMDA receptors since 
activation of these receptors leads to 
calmodulin mediated activation of nitric 
oxide synthase (Coyle, 2013). 
A second consequence of vascular 
dysfunction in the brain is that similar 
pathology should be seen in the retinas of 
schizophrenic patients. This should occur 
because there is a large body of evidence 
(see Patton et. al., 2005 for a review) which 
indicates that the state of the 
microvasculature of the retina is indicative 
of that in the brain. There is currently a large 
amount of evidence for such retinal 
pathology in schizophrenics. For example, 
82% of the 23 total chronic schizophrenic 
patients in a study by Smith et. al. (1997) 
had one or more gross ocular abnormalities. 
These abnormalities mirror gross structural 
changes in the brain, and would be expected 
if the vasculature of both systems mimicked 
each other (as has been shown) and if the 
cause of these changes in the brain was 
mediated by vasculatory system 
abnormalities (as proposed in this paper). 
When examining the fundus (the back of the 
eye, including the retina) specifically, 52% 
of schizophrenic patients examined 
displayed some abnormality, and 46% had 
vascular abnormalities in this region 
(Vannas et. al., 1961). 
This pathology in the retina, is worth 
examining in depth because it provides (as 
Patton et. al., 2005, indicate) good evidence 
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for the possibility that micro-vascular 
abnormalities such as those proposed in this 
paper's model of schizophrenia can lead to 
the functional abnormalities observed in 
schizophrenics. This can be demonstrated by 
examining the work of Cotton et. al. (1940). 
In this study, there was a high degree of 
correlation between the clinical status of the 
schizophrenic patient and the capacity of the 
retinal vascular bed. More exactly, this 
correlation was that patients who did not 
improve or who deteriorated had a relatively 
(to the improving group) small retinal 
vascular bed in a high percentage of cases. 
In contrast, patients who improved or 
recovered had a significantly larger retinal 
vascular bed. Further, longer disease 
duration was significantly correlated with 
lower retinal vascular bed volume (this 
appears to be a marker of susceptibility, and 
is not a direct result of the disease). These 
volume-status 	 relationships 	 were 
strengthened after correcting for body 
volume. If this is mirrored in the brain, this 
is consistent with the proposed model (as 
lower vascularization density should 
increase vulnerability to ischemia by 
decreasing net blood flow to the brain with a 
given blood pressure). This particular 
study's data is especially valuable because 
these patients are medication naive (the first 
neuroleptic, chlorpromazine, was initially 
marketed in the 1950s). In addition to these 
structural abnormalities, abnormal retinal 
function (paralleling the abnormal function 
of the brain) is shown in schizophrenics in 
the form of abnormal physiological 
measures such as electroretinography. 
Interestingly, the severity of these 
abnormalities correlates with the severity of 
clinical symptoms of schizophrenics 
(Balogh et. al., 2008), which is consistent 
with the proposed model because it shows 
that there is a relationship between vascular 
and functional abnormalities in the eyes of  
schizophrenics which should be mirrored in 
their brains. 
A second consequence of the idea that 
the symptoms of schizophrenia are mediated 
by a deficit of oestrogen is that there should 
be a decrease in high density lipoprotein 
(HDL) which accompanies the disorder. 
This idea follows from the finding of Bush 
(1996) that women taking oestrogen 
replacement therapy experience an increase 
in HDL levels. Thus, a decrease in this 
hormone should result in the opposite 
phenomenon: a decrease in the level of 
HDL. This concept is consistent with the 
finding that there is indeed a significant 
decrease in HDL among schizophrenics 
(Cohn et. al., 2004). This could further 
exacerbate the vascular problems underlying 
schizophrenia, as HDL is known to help 
prevent arterial disease such as 
atherosclerosis (Barter, 2005). 
To examine a different subtype of 
sequelae, a logical sequel to the ischemia 
related model of schizophrenia put forth in 
this paper is that there should be an 
accompanying leakage of fluid into the extra 
cellular matrix due to a decrease in 
membrane integrity. Also, there should be a 
decrease in the total volume of brain tissue 
(due to both sub-optimal growth and 
possible cell death) in schizophrenics 
compared to controls. Evidence consistent 
with this phenomenon is found in the 
research of Andreasen et. al. (1994), who 
state that compared with the controls, 
schizophrenia patients had a smaller average 
volume of total brain tissue and a greater 
average volume of total and ventricular 
cerebrospinal fluid (CSF). It stands to reason 
that there should be increases in total fluid 
volume if fluid is leaking into the extra 
cellular matrix. A second corollary to the 
idea of ischemia or infarct in schizophrenia 
is that there should be evidence of cellular 
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atrophy. Such evidence was found by 
Oxenstierna et. al. (1984) in the cortex and 
vermis on computed tomography (CT) scans 
of schizophrenia patients' brains. A third 
logical sequel to the idea of increased 
vulnerability to ischemia and infarct is that 
there should be a decrease in life expectancy 
that cannot be accounted for by 
symptomologies associated with the 
psychosis itself (i.e., self-injury and 
accidental death). This is exactly what was 
found by Brown (1997). A final logical 
sequel to this idea is that there should be 
evidence of oxidative stress in the brains of 
schizophrenics caused by a decrease in the 
level of available oxygen (which would 
cause oxidation in chemical reactions 
requiring more oxygen than available). Such 
evidence has been found in certain studies of 
the brains of schizophrenics after their 
deaths (Coyle, 2013). 
A final logical sequelae to the putative 
model of schizophrenia put forth here is that 
the organism afflicted with the traits which 
will eventually develop into schizophrenia 
should logically increase the chances of 
bleeding occurring when the organism is 
interfaced with another organism (i.e., 
during pregnancy). This should occur 
because of unstable vasculature as a result of 
improper vascular responses to reductions in 
oxygen. Such increases in the amount of 
bleeding during the pregnancy of the 
mothers of schizophrenics has been found 
by researchers such as Austin (2005). Neural 
damage resulting from such bleeding, on the 
whole, should be limited, however, due to 
such protective factors as the presence of 
fetal hemoglobin, which has increased 
oxygen carrying capacity compared to 
normal hemoglobin (and thus should help to 
reduce the probability of ischemic events 
occurring in the first place). This fetal 
hemoglobin should continue to protect 
significantly against damage due to the  
impaired vasodilatory response in 
schizophrenics until the third month of life, 
when fetal hemoglobin levels reach normal 
adult ones (Metaxotou-Mavromati et. al., 
1982). 
Limitations and Apparent Inconsistencies 
Due to the complex nature of the 
schizophrenic disease state, several apparent 
inconsistencies between the proposed model 
and the current literature on schizophrenia 
have been accrued thus far. The main 
inconsistency that must be reconciled is that, 
as this paper points out, NMDA receptor 
antagonists alone are not effective 
treatments for schizophrenia (although they 
may be effective as adjunct agents). This 
seems to provide evidence against the 
validity of the proposed model (as well as 
against several older models of 
schizophrenia) because NMDA receptor 
antagonists have been shown to reduce 
infarct volume in vivo (Wahlestedt et. al. 
1993), and should, by themselves, thus 
reduce symptomology progression if this 
model is correct. However, NMDA receptor 
antagonists alone have a lack of treatment 
power in schizophrenia (although they are 
used effectively as accessory treatments). 
This lack of power can be explained by the 
fact that NMDA antagonists cause 
excitatory components of neural networks to 
become uninhibited, and this in turn can 
cause neuronal damage (Onley et. al., 1999). 
Because of this, the net amount of protection 
conferred by NMDA receptor antagonists 
may be limited relative to the efficacy 
needed to attenuate symptoms. A second 
apparent inconsistency which one may have 
noticed is that O'Neil et. al. (1998) found 
that dopamine antagonists (like Haloperidol) 
were not neuroprotective in rats. This seems 
a contradiction to the explanation of the 
protective effects of Haloperidol offered 
here. However, it is important to note that 
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the rats used in that study did not have 
dysfunctions of the nitric oxide mediated 
pathway for vasodilation. Thus, the O'Neil 
study shows that once ischemia has 
occurred, dopamine antagonists are not 
neuroprotective, however it does not 
comment (as the explanation of 
Haloperidol's effects does) on the ability of 
such agents to prevent ischemia in the first 
place. 
A limitation of the proposed theory is 
that in addition to the HDL increases that 
have been shown in schizophrenics, one 
would expect low density lipoprotein (LDL) 
decreases (as is seen in women taking 
oestrogen replacement). This is not seen in 
the literature to the knowledge of the author. 
This is a limitation of the putative model, 
and perhaps future research will illuminate 
the mechanisms which prevent the expected 
LDL rise. A further limitation of the model 
proposed in this paper is if infarct or 
ischemia is occurring, then there may be 
evidence of abnormally high levels of blood 
or traces of blood in the brains of 
schizophrenics when examined. This has not 
been demonstrated in the literature thus far, 
and is a topic that should be examined more 
closely in future research. The lack of this 
demonstration thus far is should not be taken 
as a large mark against the validity of the 
model due to the fact that under most of the 
current models being used there would be no 
reason to look for the presence of blood in 
the brains of schizophrenics. Because of 
this, many studies which may have found 
blood traces may have missed them. A final 
limitation of the proposed model is that it, 
for the purposes of simplicity in this paper, 
does not differentiate between the subtypes 
of chronic schizophrenia. This putative 
model may not be equally valid for each 
subtype, and thus generalization of findings 
against or in support of this model between 
subtypes should be treated with caution  
when applying them to other subtypes of the 
disorder (e.g., familial schizophrenia vs. 
non-familial types). 
Conclusion 
In conclusion, several researchers have 
predicted that patients with schizophrenia 
"may be more susceptible to the 
neurophysiological 	 perturbations 	 of 
environmental experiences that occur in the 
context of daily life, as their compensatory 
capacity is compromised and more easily 
breached. If prolonged or recurrent, such 
perturbations can lead to a persistent state of 
dysregulation, and potentially enduring 
pathologic changes, which are at first 
functional and ultimately structural" 
(Duncan et. al., 1999). The model proposed 
in this paper conforms to these predictions 
beautifully, and, to the knowledge of the 
author, this putative mechanism has not 
been proposed prior to this article. The 
considerable (albeit circumstantial) support 
for this model (along with its surprising 
explanatory power) warrants further 
investigation. 
Several possible routes for this 
investigation are suggested by the discussion 
in this paper. For example, one possible 
region to focus on in order to find this effect 
was inadvertently identified by Rupp et. al. 
(2005). In this study, a sub region of the 
hippocampus (the subiculum) was identified 
that is active only when discriminating 
between odors and not during other 
olfactory tasks including other olfactory 
memory tasks. This area seems like a likely 
candidate for damage in schizophrenia as it 
would explain the olfactory discrimination 
deficits present in the disorder that were 
discussed in this paper. Another possible 
route for further examination of the 
proposed model is that, one could test this 
model's prediction that schizophrenics 
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should become more vulnerable to the 
induction of neural noise over time (i.e., a 
prodromal stage schizophrenic less so than 
one who has had a chronic form for several 
years). This should occur because increases 
in the net amount of damage over time 
should amplify the underlying pathology of 
the dopamine system resulting in unstable 
neural representations of stimuli. A second 
possible experiment to explore this model's 
validity is that schizophrenics with higher 
hemoglobin oxygen carrying capacity 
should have increased ages of onset of the 
disorder and possibly decreased symptom 
severity and risk of developing psychosis 
(i.e., blood oxygen carrying capacity should 
be predictive of whether and how quickly 
the onset of schizophrenia occurs in clinical 
high risk individuals). This should occur 
because higher blood oxygen levels would 
help reduce the probability of ischemic 
events occurring in the first place. 
By exploring this possible ultimate cause 
of schizophrenia through experiments such 
as these, new and more effective treatments 
and early diagnostic tools may be developed 
which improve our repertoire of methods 
that help to alleviate the immense suffering 
caused by this disease. 
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